Cytogenetic studies in bone marrow transplant recipients

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Allogeneic bone marrow transplantation (BMT) is a curative option for severe hematologic malignancies and aplastic anemia.
• Monitoring chimerism post-BMT is crucial for assessing engraftment and predicting outcomes.
• The persistence of recipient-type cells after BMT raises questions about long-term graft function and disease relapse.

Purpose of the Study:

• To investigate chimerism and cytogenetic abnormalities in patients undergoing allogeneic BMT.
• To evaluate the engraftment of donor cells and the persistence of recipient cells.
• To explore the clinical significance of persistent recipient-type mitoses in various hematologic conditions.

Main Methods:

• Chromosome studies were conducted on 24 patients receiving allogeneic BMT for aplastic anemia, chronic myeloid leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and Hodgkin's disease.
• Engraftment was assessed by donor-cell type, including sex-mismatched and sex-matched transplants.
• Recipient-type mitoses were identified and quantified in bone marrow samples post-transplantation.

Main Results:

• Donor-cell engraftment was confirmed in 21 out of 24 patients.
• Recipient-type mitoses were observed in 5 patients (1 SAA, 3 CML, 1 AML) post-BMT.
• Despite persistent Ph-positive mitoses in 3 chronic myeloid leukemia patients, all achieved complete hematological and clinical remission.

Conclusions:

• Allogeneic BMT leads to successful donor engraftment in most patients with hematologic disorders.
• The persistence of recipient-type cells after BMT occurs in a subset of patients.
• The clinical significance of cytogenetically abnormal, persisting host cells post-BMT remains undetermined and warrants further investigation.